Paraneoplastic Disorders

  title={Paraneoplastic Disorders},
  author={Eric Lancaster},
  journal={CONTINUUM: Lifelong Learning in Neurology},
  • E. Lancaster
  • Published 2017
  • Medicine
  • CONTINUUM: Lifelong Learning in Neurology
ABSTRACT Purpose of Review: Paraneoplastic neurologic syndromes target specific areas of the nervous system with pathogenic autoantibodies or T-cell responses. Each syndrome conveys a risk of particular tumors. Expanded paraneoplastic antibody testing has led to improved diagnosis but created challenges involving appropriate interpretation of test results. Recent Findings: Peripheral nervous system paraneoplastic disorders such as myasthenia gravis and Lambert-Eaton myasthenic syndrome involve… 
4 Citations

Figures and Tables from this paper

Paraneoplastic sensorimotor neuropathy and ventral cauda equina nerve root enhancement as initial presentation of small cell lung carcinoma: a case study
Onconeural negative paraneoplastic radiculoneuropathy can precede diagnosis of small cell lung carcinoma and if considered early and adequately investigated, it can allow earlier diagnosis and treatment of underlying malignancy, improving overall and neurological prognosis.


Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases
Refining and expanding the range of anti-Ma/anti-Ta associated neurological presentations and tumours clearly demonstrated that the distinction between anti- Ma and anti- Ta associated PNS is of high clinical relevance.
Amphiphysin autoimmunity: Paraneoplastic accompaniments
Only 10% of women (some with lung carcinoma) and 4% of men fulfilled diagnostic criteria for stiff‐man syndrome, and patients with isolated amphiphysin‐IgG were more likely to be women and to have myelopathy or stiff‐ man phenomena.
Anti‐neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments
We identified the IgG autoantibody ANNA‐2 (“anti‐Ri”) in 34 patients in a 12‐year period by immunofluorescence screening of sera from approximately 75,000 patients with subacute neurological
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.
The predictors of mortality and PEM evolution found in the study may be important in the design of future therapeutic protocols, and emphasize the importance of early diagnosis and treatment of the underlying tumour.
Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies
It is demonstrated that in patients with paraneoplastic neurological syndromes, the neurological symptoms and survival vary with both the type of associated onco-neural antibody and thetype of tumour.
Clinical analysis of anti-Ma2-associated encephalitis.
Anti-Ma2 encephalitis (with or without anti-Ma1 antibodies) should be suspected in patients with limbic, diencephalic or brainstem dysfunction, MRI abnormalities in these regions, and inflammatory changes in the CSF.
Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia
The antigen of a new anti-Purkinje cell antibody identified in a patient with idiopathic subacute cerebellar ataxia is characterized and a possible immune-mediated pathogenesis is suggested.
Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction.
A patient with a presumed neurodegenerative disorder of new onset, with high levels of GAD65 antibody (>20 nmol/L), merits consideration of immunotherapy.
Paraneoplastic cerebellar degeneration.
The presence of the anti-Yo antibody in patients with cerebellar symptoms warrants an aggressive approach to diagnosis and treatment of the underlying cancer, as many are curable at the time neurologic symptoms develop.